Company Overview
Entero Healthcare Solutions Limited (BSE: 544122, NSE: ENTERO, ISIN: INE010601016) reported strong financial performance for FY2025-26 with significant growth through strategic acquisitions and operational improvements.
Financial Performance Highlights
Revenue from operations reached ₹6,591.21 crore, representing 29.3% YoY growth, with like-for-like growth of 31.5% and organic growth of 15.6%. EBITDA grew 55.03% to ₹265.96 crore with margin expansion of 67 basis points to 4.03%. Profit After Tax increased 35.75% to ₹145.84 crore with PAT margin expanding 10 basis points to 2.21%. The company generated positive operating cash flow of ₹96.20 crore, a significant improvement from the outflow of ₹76.90 crore in FY25. Return metrics improved substantially with ROCE at 14.6% (up from 10.7%) and ROE at 12.5% (up from 7.7%).
Strategic Acquisitions & Expansion
Entero completed seven strategic acquisitions during FY26: Ramson Medical Distributors, Sai RK Pharma, Well Wisher Pharma, Anand Medilink, Ace Cardiopathy Solutions, Bioaide Technologies, and Anand Chemiceutics. These acquisitions contributed aggregate annualized revenue of over ₹1,000 crore and expanded the company's presence in the MedTech segment. Total consideration for acquisitions exceeded ₹3,894 million, with significant goodwill recognition of ₹2,699.51 million. The company now operates 48 subsidiaries and has completed 45+ strategic acquisitions since inception.
Operational Metrics & Market Position
The company serves 105,300+ retail pharmacies and 3,600+ hospital customers across 523 districts in India through 136 warehouses. It handles 97,500+ SKUs and maintains relationships with 3,300+ manufacturers. Working capital management improved with net working capital days reducing to 59 days in Q4 FY26 from 70 days in FY25.
Capital Structure & Financing
Borrowings increased to ₹5,666.83 million to fund acquisitions and operational requirements. The company utilized IPO proceeds of ₹9,548 million as planned: ₹1,425 million for debt repayment, ₹4,800 million for working capital, ₹2,370 million for inorganic growth, and ₹953 million for general corporate purposes. Credit rating was affirmed at 'IND A-' with stable outlook by India Ratings and Research.
Corporate Governance & AGM Details
The 8th Annual General Meeting is scheduled for August 19, 2026, through video conferencing, with e-voting from August 16-18, 2026. Agenda items include adoption of financial statements, reappointment of directors (Mr. Sujesh Vasudevan and Ms. Sandhya Gadkari Sharma as independent directors), and remuneration approvals for Mr. Prabhat Agrawal (MD & CEO) and Mr. Prem Sethi (Whole Time Director & COO). The board comprises eight directors with established committee structures.
Regulatory Compliance & Disclosures
The company maintains compliance with SEBI Listing Regulations and Companies Act requirements. Statutory auditors are M/s. M S K A & Associates LLP, with Ernst & Young LLP serving as internal auditors. No material orders were passed by courts/regulators affecting the going concern status.
Risk Factors & Mitigation
Key risks identified include M&A integration risk, supply chain disruptions, liquidity risk, product integrity, operational risk, technology risk, and people risk. The company has implemented mitigation strategies including rigorous due diligence, contingency plans, working capital optimization, direct manufacturer relationships, nationwide warehouse network, cybersecurity framework, and employee retention programs.
Forward Outlook
Entero Healthcare focuses on profitable growth, cash generation, and operational efficiency in FY27. The company will continue integrating acquired businesses, realizing synergies, expanding in the higher-margin MedTech segment, and gaining market share in the fragmented pharmaceutical distribution industry through technology-driven improvements.